Ravi A Madan1, James L Gulley. 1. Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE OF REVIEW: To provide an overview of current strategies being investigated in the development of immunotherapy in prostate cancer. RECENT FINDINGS: Development of immunotherapy in prostate cancer actually began in 2010 with FDA approval of sipuleucel-T. Given that immune checkpoint inhibitor trials have either been negative at the phase III level or underwhelming in smaller studies, it is likely that combination strategies will be required to further maximize the impact immune-based therapies on the clinical course of the disease. Emerging data suggests the presence of multiple checkpoint inhibitors in the prostate cancer tumor microenvironment highlighting the need for combination immunotherapy platforms that would potentially include androgen deprivation, chemotherapy, or radiation. SUMMARY: Preclinical and clinical data support immune-based combinations in prostate cancer and several trials are underway to better define the future of immunotherapy in prostate cancer.
PURPOSE OF REVIEW: To provide an overview of current strategies being investigated in the development of immunotherapy in prostate cancer. RECENT FINDINGS: Development of immunotherapy in prostate cancer actually began in 2010 with FDA approval of sipuleucel-T. Given that immune checkpoint inhibitor trials have either been negative at the phase III level or underwhelming in smaller studies, it is likely that combination strategies will be required to further maximize the impact immune-based therapies on the clinical course of the disease. Emerging data suggests the presence of multiple checkpoint inhibitors in the prostate cancer tumor microenvironment highlighting the need for combination immunotherapy platforms that would potentially include androgen deprivation, chemotherapy, or radiation. SUMMARY: Preclinical and clinical data support immune-based combinations in prostate cancer and several trials are underway to better define the future of immunotherapy in prostate cancer.
Authors: F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba Journal: N Engl J Med Date: 2010-06-05 Impact factor: 91.245
Authors: Tomasz M Beer; Guy T Bernstein; John M Corman; L Michael Glode; Simon J Hall; Wayne L Poll; Paul F Schellhammer; Lori A Jones; Yi Xu; Jelle W Kylstra; Mark W Frohlich Journal: Clin Cancer Res Date: 2011-05-10 Impact factor: 12.531
Authors: Victoria C Liu; Larry Y Wong; Thomas Jang; Ali H Shah; Irwin Park; Ximing Yang; Qiang Zhang; Scott Lonning; Beverly A Teicher; Chung Lee Journal: J Immunol Date: 2007-03-01 Impact factor: 5.422
Authors: Mala Chakraborty; Elizabeth K Wansley; Jorge A Carrasquillo; Sarah Yu; Chang H Paik; Kevin Camphausen; Michael D Becker; William F Goeckeler; Jeffrey Schlom; James W Hodge Journal: Clin Cancer Res Date: 2008-07-01 Impact factor: 12.531
Authors: Douglas G McNeel; Neil H Bander; Tomasz M Beer; Charles G Drake; Lawrence Fong; Stacey Harrelson; Philip W Kantoff; Ravi A Madan; William K Oh; David J Peace; Daniel P Petrylak; Hank Porterfield; Oliver Sartor; Neal D Shore; Susan F Slovin; Mark N Stein; Johannes Vieweg; James L Gulley Journal: J Immunother Cancer Date: 2016-12-20 Impact factor: 13.751
Authors: Caroline N Barquilha; Nilton J Santos; Caio C D Monção; Isabela C Barbosa; Flávio O Lima; Luis A Justulin; Nelma Pértega-Gomes; Sérgio L Felisbino Journal: Oxid Med Cell Longev Date: 2020-01-20 Impact factor: 6.543